Estroven® Difference

Commitment to Safety and Quality

Estroven’s Commitment to Safety & Quality

Every Estroven® production run undergoes a great deal of testing for purity and potency. These tests are performed by qualified laboratories, which follow standards set by various scientific agencies, including the U.S. Food and Drug Administration (FDA), U.S. Pharmacopeia (USP), NSF, AOAC, and other internationally recognized standard-setting authorities.

Estroven® Active Ingredients

Estroven’s line of multi-symptom dietary supplement menopause products have been developed with many ingredients that either reside in nature or are naturally sourced*.

Many of these ingredients, which have been around for centuries, have a long safety profile history and have demonstrated efficacy supporting their use to relieve perimenopause/menopausal symptoms.*

Sources

  1. Blumenthal, Mark. ​The ABC Clinical Guide to Herbs.​ Austin: American Botanical Council, 2003.
  2. Liske,Eckehard."TheraputicEfficacyandSafetyof​CimicifugaRacemosa​for Gynocologic Disorders." ​Advances in Natural Therapy​ 15.1 (1998): 45-53.
  3. Williamson-Hughes,PatriciaS.,BrentD.Flickinger,MarkJ.Messina,andMarkW. Empie. "Isoflavone Supplements Containing Predominantly Genistein Reduce Hot Flash Symptoms." ​Menopause​ 13.5 (2006): 831-39.
  4. Bloedon,LeAnneT.,ARobertJeffcoat,WlodekLopaczynski,MichaelJ.Schell, Tracy M. Black, Kelly J. Dix, Brian F. Thomas, Craig Albright, Marjorie G. Busby, James A. Crowell, and Steven H. Zeisel. "Safety and Pharmacokinetics of Purified Soy Isoflavones: Singledose Administration to Postmenopausal Women." ​American Journal of Clinical Nutrition​76 (2002): 1126-137.
  5. Agosta,C.,M.Atlante,andC.Benvenuti."RandomizedControlledStudyon Clinical Efficacy of Isoflavones Plus Lactobacillus Sporogenes, Associated or Not With a Natural Anxiolytic Agent in Menopause." ​Minerva Ginecol​ 63.1 (2011): 11-17.
  6. Burgess,H.J.,V.L.Revell,T.A.Molina,andC.I.Eastman."HumanPhase Response Curves to Three Days of Daily Melatonin: 0.5 Mg Versus 3.0 Mg." ​Journal of Clinical Endocrinology & Metabolism​ 95.7 (2010): 3325-331.
  7. Malhotra,Samir,GirishSawhney,andPromilaPandhi."TheTherapeuticPotential of Melatonin: A Review of the Science." ​Medscape General Medicine​. 6.2 (2004):46. Web. 8 Mar. 2012.
  8. Ciezaetal.“EffectsofGinkgobilobaonMentalFunctioninginHealthy Volunteers.” Arch Med Res. 34.5 (2003):373-81.
  9. Hartleyetal.“EffectsonCognitionandMoodinPostmenopausalWomenof 1-Week Treatment with Ginkgo biloba.” ​Pharmacology, Biochemistry, and Behavior.​ 75 (2003):711-20.
  10. Raj, S.J. and Joseph, B. Pharmacognostic and traditional properties of ​Cissus quadrangularis​ Linn- An overview. International Journal of Pharma and Bio Sciences​ ​2011​; 2(1):131-139
  11. Srivastava, A.J., ​et al.​, Pharmacognostical and Phyto-chemical Investigation of ​Cissus quadrangularis​ Linn. Stem. Int. J. of Pharma. Research and Development- Online​ ​2011​; IJPRD/2011/PUB/ARTI/VOV-3/ISSUE-1/MARCH/020
  12. Sha, U. ​Cissus quadrangularis ​L.: Phytochemicals, Traditional Uses and Pharmacological Activities- A Review. ​International Journal of Pharmacy and Pharmaceutical Sciences​ ​2011​; 3(Suppl 4):41-44
  13. Hasper, I., B. M. Ventskovskiy, R. Rettenberger, P. W. Heger, D. S. Riley, and M. Kaszkin-Bettag. "Long-Term Efficacy and Safety of the Special Extract Err 731 of Rheum Rhaponticum in Perimenopausal Women with Menopausal Symptoms." ​Menopause ​16, no. 1 (Jan-Feb 2009): 117-31.